Myostatin propeptide is the N-terminal prodomain of myostatin (GDF-8) that acts as an endogenous inhibitor of mature myostatin signaling. When myostatin is cleaved from its precursor protein, the propeptide remains non-covalently associated with the mature domain, keeping it in a latent, inactive complex. Exogenous administration of myostatin propeptide binds to and sequesters active myostatin, preventing it from signaling through activin type IIB receptors (ActRIIB) on muscle cells. This inhibition of myostatin allows increased muscle hypertrophy. Natural myostatin loss-of-function mutations in cattle (Belgian Blue), dogs (whippets), and one documented human case produce dramatic muscle hypertrophy.
Category: Muscle Growth. Evidence rating: D (animal/preclinical only).
Clinical status: Preclinical research. No human clinical trials for the propeptide form specifically. Related approaches (anti-myostatin antibodies) in Phase 2-3.
Myostatin propeptide binds to the mature myostatin dimer with high affinity, forming a latent complex that cannot interact with ActRIIB/ALK4/ALK5 receptor complexes on skeletal muscle. This prevents Smad2/3 phosphorylation and nuclear translocation, which would normally suppress muscle protein…
Research base: 0 registered clinical trials and 3 indexed publications reference Myostatin Propeptide.
Safety considerations: No human safety data for exogenous propeptide administration; Myostatin inhibition may affect cardiac muscle and tendon strength; Potential for tendon/ligament injuries if muscle strength exceeds connective tissue capacity.
Reviewed by the PeptideAtlas Editorial Team.
| Production method | recombinant |
|---|---|
| Anti-doping status | Prohibited in sport (WADA) |
| US regulatory status | Not FDA-approved. Research compound only. |
Both inhibit myostatin but through different mechanisms. The propeptide binds directly to myostatin to keep it inactive (the natural mechanism). Follistatin binds myostatin and several other TGF-beta ligands (activins, GDF-11), making it a broader inhibitor with more potential side effects.
No. ACE-031 is a soluble ActRIIB-Fc fusion protein that acts as a decoy receptor for myostatin and related ligands. Myostatin propeptide specifically sequesters the myostatin molecule itself. ACE-031 development was halted due to nosebleeds and gum bleeding in clinical trials.
Myostatin propeptide is the N-terminal prodomain of myostatin (GDF-8) that acts as an endogenous inhibitor of mature myostatin signaling. When myostatin is cleaved from its precursor protein, the propeptide remains non-covalently associated with the mature domain, keeping it in a latent, inactive complex. Exogenous administration of myostatin propeptide binds to and sequesters active myostatin,…
On the PeptideAtlas A–F scale, Myostatin Propeptide is rated D (Preclinical Only). Mostly animal or preclinical evidence
Preclinical research. No human clinical trials for the propeptide form specifically. Related approaches (anti-myostatin antibodies) in Phase 2-3.